ArticleDiabetic medicine : a journal of the British Diabetic Association2019

Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial.

A Kansal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.